Equatorial Guinea has confirmed its first outbreak of Marburg virus, related to Ebola, with a fatality rate of up to 88%. Health officials worldwide are urgently testing whether experimental vaccines can protect against the deadly illness. The World Health Organization has convened an urgent meeting to discuss the feasibility of testing Marburg vaccines in Equatorial Guinea. But control measures such as quarantine could end the outbreak before a single vaccine dose can be administered. Only the Sabin and Janssen vaccines have been tested in humans, and availability ranges from a few hundred to a few thousand doses.
Related Posts
First Human Trial of Base Editing for Cholesterol Control Raises Hope and Safety Concerns
Scientists at Verve Therapeutics in Boston conducted the inaugural human trial of base editing, using the treatment VERVE-101 to deactivate the PCSK9 gene in the liver. The gene regulates ‘bad’ cholesterol, and the one-time injection resulted in a significant LDL reduction of up to 55%. This milestone suggests a potential transformative approach to treat coronary […]
Mapping seismic risks: Identifying earthquake-prone zones for targeted preparedness.
The new map identifies earthquake-prone areas in the US, highlighting regions with heightened seismic activity and the potential for damaging earthquakes. Major fault lines, such as the San Andreas Fault in California and the Cascadia Subduction Zone in the Pacific Northwest, pose significant seismic risks. Urban areas situated near these fault lines, including Los Angeles […]
EXPLORING THE CONNECTION: Type 2 Diabetes and Migraine Risk in Chinese Populations
A groundbreaking study has delved into the intriguing relationship between type 2 diabetes (T2D) and the risk of migraine among Chinese populations. Migraine, a debilitating neurological disorder, has long been associated with various comorbidities, and emerging evidence suggests a potential connection with diabetes. The study, conducted in Chinese cohorts, sheds light on the complex interplay […]